Skip to main content

Pulse Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

PLSE$58.17+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PULSE BIOSCIENCES, INC.
Date: March 28, 2024By:/s/ Kevin P. Danahy
Kevin P. Danahy
Chief Executive Officer
(Principal Executive and Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kevin Danahy and Timothy Mitsuoka, jointly and severally, as his true and lawful attorney-in-fact and agent, with full power of substitution, each with power to act alone, to sign and execute on behalf of the undersigned any and all amendments to this Annual Report on Form 10-K, and to perform any acts necessary in order to file the same, with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requested and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes, shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Kevin P. DanahyChief Executive OfficerMarch 28, 2024
Kevin P. Danahy(Principal Executive and Principal Financial Officer)
/s/ Robert W. DugganExecutive Chairman of the Board of DirectorsMarch 28, 2024
Robert W. Duggan
/s/ Darrin R. UeckerChief Technology Officer and DirectorMarch 28, 2024
Darrin R. Uecker
/s/ Shelley D. SprayDirectorMarch 28, 2024
Shelley D. Spray
/s/ Manmeet S. SoniDirectorMarch 28, 2024
Manmeet S. Soni
/s/ Mahkam ZanganehDirectorMarch 28, 2024
Mahkam Zanganeh
/s/ Richard A. van den BroekDirectorMarch 28, 2024
Richard A. van den Broek
/s/ Timothy H. MitsuokaCorporate ControllerMarch 28, 2024
Timothy H. Mitsuoka(Principal Accounting Officer)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.